人參及人參皂苷於純系小鼠之馬兜鈴酸腎炎模型的藥效評估

陳世銘
台北醫學大學
馬兜鈴酸 (aristolochic acid, AA) 在中草藥引起的腎病變中扮演重要的角色。本研究的目的為藉由投予AA引起馬兜鈴酸腎病變 (aristolochic acid nephropathy, AAN)，以評估人參 (ginseng extrat, GE) 及其成份ginsenoside Rb1、Rd及Rg1對AAN的改善效果。
給予純系小鼠C3H/He (6 week-old male) 3.0 μg/mL AA當飲用水，連續56天，之後治療組分別經口投予GE (125、250、500 mg/kg)或純成份ginsenoside (Rb1、Rd、Rg1) 5 mg/kg連續14天，對照組給予等量蒸餾水，Normal組則全程給予蒸餾水。
藉由測定尿蛋白，尿中N-acetyl-beta-D-glucosaminidase (NAG) 與血中blood urea nitrogen (BUN) 及creatinine，以評估小鼠腎功能；腎組織使用PAS染色觀察病理組織改變，並進行免疫螢光染色 (TGF-β，MMP-9，HGF)，以辨識損傷部位之特異性抗原。
實驗結果顯示，投予GE 250 mg/kg，ginsenoside Rb1, Rg1之治療組的尿蛋白、NAG、BUN、SCr及血糖值都有降低；組織學及免疫螢光染色觀察發現腎組織損傷的情形皆有緩解。根據以上結果發現，人參濃縮劑部分，GE 250的療效最好，其次依序為GE 500 及GE 125。人參皂苷部分，有效程度依序為Rg1、Rb1、Rd。
關鍵字：馬兜鈴酸腎病變，人參，人參皂苷ginsenoside Rb1，Rd，Rg1，乙型轉型生長因子，基質金屬蛋白分解酶，肝細胞生長因子。

Effect of ginseng and ginsenosides on aristolochic acid-induced nephropathy in inbred mice

Chen Shih-Ming
Taipei Medical University
Aristolochic acid (AA) has been demonstrated to play a crucial role in Chinese herbs nephropathy. The purpose of this study was to evaluate the therapeutic effect of ginseng extrat (GE) and its active component, ginsenoside (GS), on AA-induced nephropathy.
AA was dissolved in distilled water (3μg/ml) as drinking water to C3H/He mice (6 week-old male) for 56 days. The treatment groups were administered orally with GE (125, 250, 500 mg/kg) or ginsenosides (Rb1, Rd, Rg1 5 mg/kg) once daily for 14 days. The control group was administered with distilled water. The normal group was only administered with distilled water throughout the experiment. 
Urine protein (UP), urine N-acetyl-beta-D-glucosaminidase (NAG), blood urea nitrogen (BUN) and serum creatinine were determined to evaluate renal function. Renal tissues were served to histological examination (PAS stain and immunofluorescence). The antibodies, including TGF-β (transforming growth factor-β), MMP-9 (matrix metalloproteinase-9), HGF (hepatocyte growth factor), were chosen to recognize the specific antigens in injury sites.
關鍵字：Aristolochic acid nephropathy (AAN), ginseng, ginsenoside Rb1, Rd, Rg1, TGF-β (transforming growth factor-β), MMP-9 (matrix metalloproteinase-9), HGF (Hepatocyte Growth Factor)